Price Action Don’t Lie: Is Eagle Pharmaceuticals Inc a Buy? The Stock Rises Again

Price Action Don't Lie: Is Eagle Pharmaceuticals Inc a Buy? The Stock Rises Again

The stock of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) is a huge mover today! About 205,542 shares traded hands. Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has declined 3.00% since March 7, 2016 and is downtrending. It has underperformed by 10.60% the S&P500.
The move comes after 6 months positive chart setup for the $1.05 billion company. It was reported on Oct, 10 by We have $108.93 PT which if reached, will make NASDAQ:EGRX worth $640.50M more.

Analysts await Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to report earnings on November, 9. They expect $0.84 EPS, up 229.23% or $1.49 from last year’s $-0.65 per share. EGRX’s profit will be $13.04M for 20.14 P/E if the $0.84 EPS becomes a reality. After $0.80 actual EPS reported by Eagle Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 5.00% EPS growth.

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Ratings Coverage

Out of 3 analysts covering Eagle Pharma (NASDAQ:EGRX), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Eagle Pharma has been the topic of 5 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Wednesday, December 9 by Mizuho. Piper Jaffray maintained it with “Overweight” rating and $119 target price in Wednesday, July 29 report. The rating was downgraded by Mizuho on Monday, June 20 to “Neutral”. The stock of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has “Outperform” rating given on Tuesday, May 10 by RBC Capital Markets. The rating was maintained by Mizuho on Friday, February 26 with “Buy”.

According to Zacks Investment Research, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey.”

More notable recent Eagle Pharmaceuticals Inc (NASDAQ:EGRX) news were published by: which released: “Why Eagle Pharmaceuticals, Inc. Skyrocketed 27.8% Today” on June 10, 2016, also with their article: “Why Eagle Pharmaceuticals Inc. Flew 38.5% Higher in August” published on September 09, 2016, published: “Eagle Pharmaceuticals Announces Changes to Its Board of Directors; Director …” on July 05, 2016. More interesting news about Eagle Pharmaceuticals Inc (NASDAQ:EGRX) were released by: and their article: “Eagle Pharmaceuticals Achieves Milestone to Receive $15 Million Payment for …” published on December 08, 2015 as well as‘s news article titled: “Eagle Pharmaceuticals, Inc. Reports First Quarter 2016 Results; Bendeka …” with publication date: May 09, 2016.

EGRX Company Profile

Eagle Pharmaceuticals, Inc., incorporated on January 2, 2007, is a specialty pharmaceutical company. The Firm focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka). The Firm has over four product candidates in advanced stages of development, and/or under review for approval by the United States Food and Drug Administration (FDA), which include EP-6101 Kangio ready-to-use (RTU) bivalirudin; EP-4104 (dantrolene sodium) (EP-4104) for exertional heat stroke (EHS), and EP-5101 (pemetrexed) (EP-5101). The Company’s near-term product candidate, Kangio is a liquid intravenous form of Angiomax for percutaneous transluminal angioplasty.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment